Empaglif 25 mg (Tablet)
Unit Price: ৳ 50.00 (2 x 10: ৳ 1,000.00)
Strip Price: ৳ 500.00
Medicine Details
Category | Details |
---|---|
Generic | Empagliflozin |
Company | Aristopharma ltd |
Also available as |
Indications
- Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
- To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease
Pharmacology
Sodium glucose co-transporter-2 (SGLT-2) inhibitor
Dosage & Administration
Recommended dose of 10 mg once daily, taken in the morning, with or without food. Dose may be increased to 25 mg once daily in patients tolerating the medication
Interaction
- Co-administration with diuretics may increase urine volume
- Co-administration with insulin or insulin secretagogues increases the risk for hypoglycemia
- Monitoring glycemic control with urine glucose tests and 1,5-AG assay is not recommended while taking SGLT2 inhibitors
Contraindications
Contraindicated in patients with history of serious hypersensitivity reaction, severe renal impairment, end-stage renal disease, or dialysis
Side Effects
- Urinary tract infections
- Female genital mycotic infections
- Dehydration
- Hypotension
- Weakness
- Dizziness
- Increased thirstiness
Pregnancy & Lactation
- Not adequately studied in pregnant women
- Use during pregnancy only if potential benefit justifies potential risk to the fetus
- Not recommended when breastfeeding
Precautions & Warnings
- Assessment of renal function is recommended prior to initiation and periodically thereafter
- Not initiated in patients with eGFR less than 45 ml/min/1.73 m^2
- No dose adjustment needed in patients with eGFR greater than or equal to 45 ml/min/1.73 m^2
Overdose Effects
Supportive measures should be employed in the event of an overdose; removal by hemodialysis has not been studied
Therapeutic Class
Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
Storage Conditions
Store in a cool & dry place (below 30°C), protected from light & moisture, and out of the reach of children
Chemical Structure
- Molecular Formula: C23H27ClO7
- Chemical Structure: Image available at provided link
Common Questions about Empaglif 25 mg Tablet
- Reduces reabsorption of glucose from kidney
- Used to improve glycemic control in adults
- May be unsafe to use during pregnancy
- Probably unsafe to use during breastfeeding
- Should be used cautiously in patients with underlying kidney disease
- No dose adjustment needed for patients with mild to moderate liver disease